Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With
Fangling Hu1, Liang Guo1, Jieqing Yu2
1Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nangchang University, Nanchang, China.
Abstract:
Objective: The efficacy of anlotinib as a treatment for head-and-neck squamous cell carcinoma (HNSCC) has been little explored. Here, we used patient-derived xenografts (PDXs) to this end. Methods: Fresh tumor tissues of HNSCC patients were screened in terms of in vitro drug sensitivity using the MTT assay. Patient PDXs were used to confirm the anti-tumor effects of anlotinib in vivo. After the medication regimen was complete, the tumor volume changes in mice were calculated. Apoptosis was measured using the TUNEL assay. The cell proliferation and apoptosis levels of PDXs yielded data on the utility of anlotinib treatment in vivo. Results: Anlotinib suppressed the in vitro proliferation of nine tumor tissues by an average of 51.05 ± 13.74%. Anlotinib also significantly inhibited the growth of three PDXs in mice (tumor growth inhibition 79.02%). The expression levels of Ki-67 and proliferating cell nuclear antigen after anlotinib treatment were significantly lower than those in the controls. The negative and positive controls exhibited no and some apoptosis, respectively, whereas the anlotinib group evidenced extensive apoptosis. Conclusion: Anlotinib suppressed HNSCC growth in vitro and in vivo (by inhibiting cell proliferation and promoting apoptosis), suggesting that anlotinib can potentially treat HNSCC.
Insights
Anlotinib effectively inhibited head-and-neck squamous cell carcinoma (HNSCC) growth in laboratory tests and in patient-derived xenografts by reducing proliferation and increasing apoptosis. This suggests anlotinib
Area of Science:
- Oncology
- Pharmacology
Background:
- Head-and-neck squamous cell carcinoma (HNSCC) remains a significant clinical challenge.
- The therapeutic potential of anlotinib in HNSCC treatment is largely unexplored.
Purpose of the Study:
- To investigate the efficacy of anlotinib in treating head-and-neck squamous cell carcinoma (HNSCC).
- To evaluate anlotinib's anti-tumor effects using patient-derived xenografts (PDXs) and in vitro assays.
Main Methods:
- In vitro drug sensitivity screening of HNSCC tumor tissues using the MTT assay.
- In vivo evaluation of anlotinib's anti-tumor effects in HNSCC patient-derived xenografts (PDXs) in mice.
- Assessment of tumor volume changes, cell proliferation (Ki-67, PCNA), and apoptosis (TUNEL assay) post-anlotinib treatment.
Main Results:
- Anlotinib suppressed in vitro proliferation of nine HNSCC tumor tissues by an average of 51.05%.
- Anlotinib significantly inhibited the growth of three HNSCC PDXs in mice, achieving 79.02% tumor growth inhibition.
- Anlotinib treatment led to significantly reduced expression of proliferation markers (Ki-67, PCNA) and induced extensive apoptosis in PDXs.
Conclusions:
- Anlotinib demonstrates significant anti-tumor activity against HNSCC in vitro and in vivo.
- Anlotinib exerts its effects by inhibiting cancer cell proliferation and promoting apoptosis.
- Anlotinib holds potential as a novel therapeutic agent for head-and-neck squamous cell carcinoma.
More Related Videos
07:10Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents
Published on: March 7, 2011
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020